Literature DB >> 28529243

Over-Expression of miR-21 and Lower PTEN Levels in Wilms' Tumor with Aggressive Behavior.

Mingyu Cui1, Wei Liu1, Lijuan Zhang1, Feng Guo1, Yang Liu1, Fang Chen2, Ting Liu3, Rui Ma4, Rongde Wu1.   

Abstract

Wilms' tumor (WT) is the most common pediatric kidney tumor. MiR-21 is one of the most frequently overexpressed microRNAs in solid tumors, while phosphatase and tensin homolog deleted from chromosome 10 (PTEN) is the most highly mutated tumor suppressor gene. The aim of this study was to investigate the relationship between miR-21 and PTEN in WT. The expression levels of miR-21 and the PTEN protein were determined by qRT-PCR and Western blot analyses in WT specimens, respectively. In WT tissues, the miR-21 expression levels were significantly higher and the PTEN protein levels were significantly lower, compared to the adjacent non-tumorous renal tissues. The higher levels of miR-21 and lower levels of PTEN were correlated with age (> 24 months), late clinical stage, unfavorable histopathological type and lymphatic metastasis. A univariate linear regression analysis indicated a significant correlation between higher miR-21 levels and lower PTEN levels. Using the SK-NEP-1 WT cell line, we showed that the decreased expression levels of miR-21 promoted cell proliferation and invasion, but inhibited apoptosis. Importantly, lowered expression levels of miR-21 increased the expression levels of PTEN protein and decreased the expression levels of phosphoinositide 3-kinase (PI3K) and phosphorylated protein kinase B (p-AKT), each of which functions in the downstream signaling pathway. Dual luciferase-reporter assays indicated that PTEN mRNA was a direct target of miR-21. In conclusion, higher miR-21 levels and lower PTEN protein levels are predictive biomarkers for poor prognosis of WT patients. Over-expression of miR-21 promotes aggressive behavior of WT by targeting PTEN.

Entities:  

Keywords:  PTEN; SK-NEP-1 cell; Wilms’ tumor; miR-21; target gene

Mesh:

Substances:

Year:  2017        PMID: 28529243     DOI: 10.1620/tjem.242.43

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  9 in total

1.  Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor.

Authors:  Dinesh Kumar Sahu; Neetu Singh; Mumani Das; Jiledar Rawat; Devendra Kumar Gupta
Journal:  Pediatr Surg Int       Date:  2022-09-15       Impact factor: 2.003

2.  Investigating the dysfunctional pathogenesis of Wilms' tumor through a multidimensional integration strategy.

Authors:  Wenbiao Chen; Jia Zhuang; Lan Gong; Yong Dai; Hongyan Diao
Journal:  Ann Transl Med       Date:  2019-04

3.  Comprehensive analysis of the long non-coding RNA-associated competitive endogenous RNA network reveals novel prognostic biomarkers in Wilms' tumor.

Authors:  Zifeng Liu; Wenbo Zhao; Yuqing Ren; Chang Liu; Xun Liu; Jian Xiao
Journal:  Oncol Lett       Date:  2020-03-31       Impact factor: 2.967

4.  miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting TGFBR1 gene.

Authors:  Hailei Wang; Chunyan Lou; Na Ma
Journal:  Cancer Manag Res       Date:  2019-02-19       Impact factor: 3.989

5.  MiR-21 Expression in Wilms' Tumor.

Authors:  Navid Bazzaz; Nazila Nouraee; Ali Zare-Mirzaie; Maryam Shahali; Syed Jawad Mowla; Mohammad Vasei
Journal:  Iran J Pathol       Date:  2018-09-25

6.  Effect of miR-301a/PTEN pathway on the proliferation and apoptosis of cervical cancer.

Authors:  Li-Na Peng; Wen-Tian Shi; Huan-Rong Feng; Chuan-Yu Wei; Qi-Nan Yin
Journal:  Innate Immun       Date:  2019-04-03       Impact factor: 2.680

Review 7.  microRNAs Make the Call in Cancer Personalized Medicine.

Authors:  Simone Detassis; Margherita Grasso; Valerio Del Vescovo; Michela A Denti
Journal:  Front Cell Dev Biol       Date:  2017-09-22

8.  Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth.

Authors:  Liang-Qi Cao; Xue-Wei Yang; Yu-Bin Chen; Da-Wei Zhang; Xiao-Feng Jiang; Ping Xue
Journal:  Mol Cancer       Date:  2019-10-27       Impact factor: 27.401

Review 9.  Research advances in the targeted therapy and immunotherapy of Wilms tumor: a narrative review.

Authors:  Bo Hong; Rui Dong
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.